BeiGene
BGNE
#881
Rank
ยฃ17.79 B
Marketcap
ยฃ159.02
Share price
-0.65%
Change (1 day)
-2.38%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of June 2024 : ยฃ2.60 Billion

According to BeiGene 's latest financial reports the company has ยฃ2.60 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$ยฃ2.77 B-23.37%
2022-12-31$ยฃ3.62 B-20.25%
2021-12-31$ยฃ4.54 B60.05%
2020-12-31$ยฃ2.83 B280.47%
2019-12-31$ยฃ0.74 B-45.99%
2018-12-31$ยฃ1.38 B172.88%
2017-12-31$ยฃ0.50 B77.01%
2016-12-31$ยฃ0.28 B470.3%
2015-12-31$ยฃ50.15 M203.01%
2014-12-31$ยฃ16.55 M-170.5%
2013-12-31$-ยฃ23.48 Million

Net assets for similar companies or competitors

Company Net assets differencediff. Country
ยฃ4.65 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.07 B-58.55%๐Ÿ‡บ๐Ÿ‡ธ USA